Review
Immunology
Peilong Li, Nan Wang, Yi Zhang, Chuanxin Wang, Lutao Du
Summary: HLA-G, a non-classic MHC class I molecule, is widely expressed in tumor environment where it plays a key role in immune escape, potentially important for cancer diagnosis and prognosis. However, due to its multiple subtypes, evaluating HLA-G expression in tumors is challenging.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Hui-Hui Xu, Jun Gan, Dan-Ping Xu, Lu Li, Wei-Hua Yan
Summary: The study comprehensively analyzed the role of HLA-G in various types of cancer, revealing associations with immune checkpoints, pathological stages, prognosis, and tumor-infiltrating immune cells. The differential expression of HLA-G across different tumors may be explained by multiple mutations and methylation status. Functional enrichment analysis showed that HLA-G is primarily related to T cell-mediated immunity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Zhou Zhang, Pengli Zhou, Mingyue Liu, Bing Pei
Summary: The high expression of PRDX1 is closely associated with the onset, progression, and prognosis of gastrointestinal cancers, particularly showing high diagnostic efficacy in colorectal cancer.
Review
Immunology
Simon Jasinski-Bergner, Dominik Schmiedel, Ofer Mandelboim, Barbara Seliger
Summary: This review provides a summary of the expression, regulation, function, and impact of HLA-G in the context of different viral infections, including virus-associated cancers. It emphasizes the potential use of HLA-G as a novel diagnostic and prognostic biomarker for viral infections, as well as a therapeutic target.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Jose Manuel Martin-Villa, Christian Vaquero-Yuste, Marta Molina-Alejandre, Ignacio Juarez, Fabio Suarez-Trujillo, Adrian Lopez-Nares, Jose Palacio-Gruber, Luis Barrera-Gutierrez, Eduardo Fernandez-Cruz, Carmen Rodriguez-Sainz, Antonio Arnaiz-Villena
Summary: HLA-G is a non-classical HLA class I molecule with immunomodulatory properties that is involved in various processes such as organ transplantation, viral infections, cancer progression, and autoimmune diseases. Its immunosuppressive effect is exerted through interaction with its receptors on immune cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Yongan Song, Leonardo Kelava, Istvan Kiss
Summary: Lung cancer, particularly lung adenocarcinoma (LUAD), is a major public health challenge and the leading cause of cancer-related deaths worldwide. MicroRNAs (miRNAs) have crucial roles in gene regulation and their involvement in cancer is extensively studied. However, there is a gap in the literature regarding the specific role of miRNAs in LUAD. This review provides an inclusive overview of the research conducted on miRNAs in the context of LUAD, highlighting their potential diagnostic, prognostic, and therapeutic implications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Xiaoru Xin, Qianan Li, Jinyong Fang, Tiejun Zhao
Summary: Long non-coding RNAs are crucial regulators of gene expression and physiological processes, with HOX transcript antisense RNA (HOTAIR) being an oncogenic lncRNA highly upregulated in various human cancers. Targeting HOTAIR shows therapeutic potential in cancer treatment, with studies focusing on drug resistance, survival, and potential therapies. Preclinical studies are needed to further explore molecular mechanisms underlying HOTAIR dysregulation and efficient drug delivery methods in vivo.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Guoxu Zheng, Zhangyan Guo, Weimiao Li, Wenjin Xi, Baile Zuo, Rui Zhang, Weihong Wen, An-Gang Yang, Lintao Jia
Summary: This study revealed that nonclassical histocompatibility antigen HLA-G desensitizes breast cancer cells to trastuzumab by binding to NK cell receptor KIR2DL4, leading to drug resistance. Trastuzumab treatment induces aberrant cytokine production, reinforcing HLA-G/KIR2DL4 signaling, while TGF-β and IFN-γ impair NK cell cytotoxicity. Targeting HLA-G and PD-L1/PD-1 may improve the efficacy of trastuzumab in treating resistant breast cancer.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Review
Biochemistry & Molecular Biology
Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiulin Tang, Feng Bi
Summary: KRAS is a commonly mutated oncogene in colorectal cancer, leading to aberrant activation of the KRAS protein and stimulation of downstream signaling pathways, resulting in cell proliferation and survival, ultimately leading to tumorigenesis. Patients with KRAS mutations in CRC have poor prognosis.
Article
Cell Biology
Ruiqi Liu, Xiaodong Liang, Haiwei Guo, Shuang Li, Weiping Yao, Chenfang Dong, Jiajun Wu, Yanwei Lu, Jianming Tang, Haibo Zhang
Summary: STMN1 belongs to the stathmin gene family and encodes a cytoplasmic phosphorylated protein called stathmin1. It acts as a structural microtubule-associated protein (MAP) that prevents the aggregation of microtubule protein dimers, leading to microtubule instability. Its elevated expression is associated with various malignancies and inhibiting its expression can interfere with tumor cell division. Furthermore, STMN1 expression affects tumor cell sensitivity to anti-microtubule drug analogs.
CELLULAR SIGNALLING
(2023)
Article
Genetics & Heredity
Wei Liu, Jin-Mou Yi, Yi Liu, Cong Chen, Kai-Xuan Zhang, Cheng Zhou, Hui-En Zhan, Liang Zhao, Stephanie Morales, Xie-Lan Zhao, Hui Zeng
Summary: The study revealed that CDK6 might be a potential diagnostic and prognostic biomarker in non-APL AML patients, showing correlations with genes associated with leukemia and microRNAs related to anticancer effects.
FRONTIERS IN GENETICS
(2021)
Article
Multidisciplinary Sciences
Maria Belen Palma, Diana Tronik-Le Roux, Guadalupe Amin, Sheila Castaneda, Alan M. Mobbs, Maria Agustina Scarafia, Alejandro La Greca, Marina Daouya, Isabelle Poras, Ana Maria Inda, Lucia N. Moro, Edgardo D. Carosella, Marcela N. Garcia, Santiago G. Miriuka
Summary: The study successfully achieved downregulation of HLA-G expression in tumor cells using CRISPR/Cas9 gene editing, leading to enhanced in vitro immune cell response. This finding provides an important foundation for the development of novel clinical immunotherapeutic approaches in cancer.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Ning Wang, Lingye Zhu, Liangxing Wang, Zhifa Shen, Xiaoying Huang
Summary: The study comprehensively analyzed the potential functions of SHCBP1 in various cancer types, revealing its upregulation and its role as a diagnostic, prognostic, and immune-related biomarker.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2022)
Review
Immunology
Simone Negrini, Paola Contini, Giuseppe Murdaca, Francesco Puppo
Summary: Allergy is an inflammatory process triggered by immune events. HLA-G molecules play a crucial immunoregulatory role in allergic diseases by specifically expressing and secreting as inhibitory factors during the allergic reaction.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Fanqi Wu, Longguo Zhang, Pingfan Wu, Yi Wu, Tao Zhang, Dekui Zhang, Jinhui Tian
Summary: This study aimed to assess the impact of dysregulated snoRNAs on cancers. The results showed that dysregulated snoRNAs were associated with the clinicopathological characteristics, survival rate, and tumor cell phenotypes of cancer patients. Additionally, snoRNAs can modulate the biological processes and signaling pathways of cancer cells. Therefore, dysregulated snoRNAs may serve as new biomarkers for clinical assessment, diagnosis, and prognostic prediction of cancer patients, and provide a potential therapeutic strategy for cancer treatment.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
(2022)
